Ovarian Cancer
A Phase 3, Randomized, Open-Label Study of Combination Therapy with Avutometinib plus Defactinib Versus Investigator's Choice of Treatment in Patients with Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) (VS-6766-301)
- Details
ClinicalTrials.gov ID:
NCT06072781
Diagnosis Type:
NA
USOR Number:
- Address
,
P: